ADAM9 is involved in pathological retinal neovascularization

Molecular and Cellular Biology

Volumn 29, Issue 10, 2009, Pages 2694-2703

  Guaiquil, Victor ^a   Swendeman, Steven ^a   Yoshida, Tsunehiko ^b   Chavala, Sai ^c   Campochiaro, Peter A ^b   Blobel, Carl P ^a,d  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b JOHNS HOPKINS UNIVERSITY   (United States)

^c DUKE UNIVERSITY MEDICAL CENTER   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADAM PROTEIN; ADAM9 PROTEIN; ANGIOPOIETIN RECEPTOR; CD40 ANTIGEN; EPHRIN RECEPTOR B4; UNCLASSIFIED DRUG; VASCULAR CELL ADHESION MOLECULE 1; VASCULAR ENDOTHELIAL CADHERIN; VASCULOTROPIN RECEPTOR 2; ADAM9 PROTEIN, MOUSE; MEMBRANE PROTEIN; OXYGEN; REACTIVE OXYGEN METABOLITE;

ANIMAL CELL; ANIMAL CELL CULTURE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; MELANOMA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RETINA NEOVASCULARIZATION; RETINOPATHY; TRANSGENIC MOUSE; TUMOR GROWTH; UPREGULATION; WILD TYPE; ANIMAL; C57BL MOUSE; CELL LINE; FEMALE; GENETICS; HUMAN; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY;

MUS;

ADAM PROTEINS; ANIMALS; CELL LINE; FEMALE; HUMANS; MALE; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OXYGEN; REACTIVE OXYGEN SPECIES; RETINAL NEOVASCULARIZATION;

EID: 66349106575     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.01460-08     Document Type: Article

References (30)

1. Blobel, C. P. 2005. ADAMs: key players in EGFR-signaling, development and disease. Nat. Rev. Mol. Cell Biol. 6:32-43.
2. Blobel, C. P., D. G. Myles, P. Primakoff, and J. W. White. 1990. Proteolytic processing of a protein involved in sperm-egg fusion correlates with acquisition of fertilization competence. J. Cell Biol. 111:69-78.
3. Bradley, J., M. Ju, and G. S. Robinson. 2007. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 10:141-148.
4. Chen, J., and L. E. Smith. 2007. Retinopathy of prematurity. Angiogenesis 10:133-140.
5. Folkman, J., and D. Ingber. 1992. Inhibition of angiogenesis. Semin. Cancer Biol. 3:89-96.
6. Friedlander, M., M. I. Dorrell, M. R. Ritter, V. Marchetti, S. K. Moreno, M. El-Kalay, A. C. Bird, E. Banin, and E. Aguilar. 2007. Progenitor cells and retinal angiogenesis. Angiogenesis 10:89-101.
7. Fruttiger, M. 2007. Development of the retinal vasculature. Angiogenesis 10:77-88.
8. Hammes, H. P., M. Brownlee, A. Jonczyk, A. Sutter, and K. T. Preissner. 1996. Subcutaneous injection of a cyclic peptide antagonist of vitronectin receptor-type integrins inhibits retinal neovascularization. Nat. Med. 2:529-533.
9. Hardy, P., I. Dumont, M. Bhattacharya, X. Hou, P. Lachapelle, D. R. Varma, and S. Chemtob. 2000. Oxidants, nitric oxide and prostanoids in the developing ocular vasculature: a basis for ischemic retinopathy. Cardiovasc. Res. 47:489-509.
10. Horiuchi, K., S. Le Gall, M. Schulte, T. Yamaguchi, K. Reiss, G. Murphy, Y. Toyama, D. Hartmann, P. Saftig, and C. Blobel. 2007. Substrate selectivity of EGF-receptor ligand sheddases and their regulation by phorbol esters and calcium influx. Mol. Biol. Cell 18:176-188.
11. Horiuchi, K., G. Weskamp, L. Lum, H. P. Hammes, H. Cai, T. A. Brodie, T. Ludwig, R. Chiusaroli, R. Baron, K. T. Preissner, K. Manova, and C. P. Blobel. 2003. Potential role for ADAM15 in pathological neovascularization in mice. Mol. Cell. Biol. 23:5614-5624.
12. Khong, T. L., H. Larsen, Y. Raatz, and E. Paleolog. 2007. Angiogenesis as a therapeutic target in arthritis: learning the lessons of the colorectal cancer experience. Angiogenesis 10:243-258.
13. Nath, D., P. M. Slocombe, A. Webster, P. E. Stephens, A. J. Docherty, and G. Murphy. 2000. Meltrin gamma (ADAM-9) mediates cellular adhesion through alpha(6)beta(1)integrin, leading to a marked induction of fibroblast cell motility. J. Cell Sci. 113:2319-2328.
14. Olsson, A. K., A. Dimberg, J. Kreuger, and L. Claesson-Welsh. 2006. VEGF receptor signalling - in control of vascular function. Nat. Rev. Mol. Cell Biol. 7:359-371.
15. Peduto, L., V. E. Reuter, D. R. Shaffer, H. I. Scher, and C. P. Blobel. 2005. Critical function for ADAM9 in mouse prostate cancer. Cancer Res. 65: 9312-9319.
16. Roghani, M., J. D. Becherer, M. L. Moss, R. E. Atherton, H. Erdjument-Bromage, J. Arribas, R. K. Blackburn, G. Weskamp, P. Tempst, and C. P. Blobel. 1999. Metalloprotease-disintegrin MDC9: intracellular maturation and catalytic activity. J. Biol. Chem. 274:3531-3540.
17. Sahin, U., G. Weskamp, Y. Zheng, V. Chesneau, K. Horiuchi, and C. P. Blobel. 2006. A sensitive method to monitor ectodomain shedding of ligands of the epidermal growth factor receptor. Methods Mol. Biol. 327:99-113.
18. Sahin, U., G. Weskamp, H. M. Zhou, S. Higashiyama, J. J. Peschon, D. Hartmann, P. Saftig, and C. P. Blobel. 2004. Distinct roles for ADAM10 and ADAM17 in ectodomain shedding of six EGFR-ligands. J. Cell Biol. 164: 769-779.
19. Sherris, D. 2007. Ocular drug development - future directions. Angiogenesis 10:71-76.
20. Shigemura, K., S. Y. Sung, H. Kubo, R. S. Arnold, M. Fujisawa, A. Gotoh, H. E. Zhau, and L. W. Chung. 2007. Reactive oxygen species mediate androgen receptor- and serum starvation-elicited downstream signaling of ADAM9 expression in human prostate cancer cells. Prostate 67:722-731.
21. Smith, L. E., E. Wesolowski, A. McLellan, S. K. Kostyk, R. D'Amato, R. Sullivan, and P. A. D'Amore. 1994. Oxygen-induced retinopathy in the mouse. Investig. Ophthalmol. Vis. Sci. 35:101-111.
22. Sung, S. Y., H. Kubo, K. Shigemura, R. S. Arnold, S. Logani, R. Wang, H. Konaka, M. Nakagawa, S. Mousses, M. Amin, C. Anderson, P. Johnstone, J. A. Petros, F. F. Marshall, H. E. Zhau, and L. W. Chung. 2006. Oxidative stress induces ADAM9 protein expression in human prostate cancer cells. Cancer Res. 66:9519-9526.
23. Tobe, T., S. Ortega, J. D. Luna, H. Ozaki, N. Okamoto, N. L. Derevjanik, S. A. Vinores, C. Basilico, and P. A. Campochiaro. 1998. Targeted disruption of the FGF2 gene does not prevent choroidal neovascularization in a murine model. Am. J. Pathol. 153:1641-1646.
24. Weskamp, G., H. Cai, T. A. Brodie, S. Higashyama, K. Manova, T. Ludwig, and C. P. Blobel. 2002. Mice lacking the metalloprotease-disintegrin MDC9 (ADAM9) have no evident major abnormalities during development or adult life. Mol. Cell. Biol. 22:1537-1544.
25. Weskamp, G., J. R. Krätzschmar, M. Reid, and C. P. Blobel. 1996. MDC9, a widely expressed cellular disintegrin containing cytoplasmic SH3 ligand domains. J. Cell Biol. 132:717-726.
26. Xie, B., J. Shen, A. Dong, M. Swaim, S. F. Hackett, L. Wyder, S. Worpenberg, S. Barbieri, and P. A. Campochiaro. 2008. An Adam15 amplification loop promotes vascular endothelial growth factor-induced ocular neovascularization. FASEB J. 22:2775-2783.
27. Yeh, P. T., C. M. Yang, J. S. Huang, C. T. Chien, C. H. Yang, Y. H. Chiang, and Y. F. Shih. 2008. Vitreous levels of reactive oxygen species in proliferative diabetic retinopathy. Ophthalmology 115:734-737.
28. Zheng, Y., P. Saftig, D. Hartmann, and C. Blobel. 2004. Evaluation of the contribution of different ADAMs to TNFα shedding and of the function of the TNFα ectodomain in ensuring selective stimulated shedding by the TNF convertase (TACE/ADAM17). J. Biol. Chem. 279:42898-42906.
29. Zheng, Y., J. Schlondorff, and C. P. Blobel. 2002. Evidence for regulation of the tumor necrosis factor alpha-convertase (TACE) by protein-tyrosine phosphatase PTPH1. J. Biol. Chem. 277:42463-42470.
30. Zigrino, P., J. Steiger, J. W. Fox, S. Loffek, A. Schild, R. Nischt, and C. Mauch. 2007. Role of ADAM-9 disintegrin-cysteine-rich domains in human keratinocyte migration. J. Biol. Chem. 282:30785-30793.